NOTVQ Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 0.01
- P/S (TTM)
- 0.00
- EV/EBITDA
- 68.69
Profitability & growth
- ROE (TTM)
- -74.1%
- Operating margin
- -16.0%
- Revenue growth YoY
- -5.4%
- Dividend yield
- —
- Beta
- 3.77
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Inotiv, Inc.
Company profileInotiv, Inc. (NOTVQ) is a leading preclinical contract research organization specializing in drug development and safety assessment services for the biotech and pharmaceutical industries. The company offers a comprehensive range of solutions, including nonclinical imaging, pharmacology, and toxicology, to support the development of new therapeutics. Driven by innovation and a commitment to scientific excellence, Inotiv leverages advanced technologies and a highly skilled workforce to deliver valuable insights and data that facilitate the drug discovery process. With a growing portfolio of…
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 2701 KENT AVENUE, WEST LAFAYETTE, IN
- Fiscal year end
- September
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer